Alzamend Neuro is trading at $1.49, up 12.03%, in pre-market; no verified company-specific announcement explaining the move was found.
- Company news listings show no new October 20 headline.
- Biotech-sector context is negative, while broad-index declines are modest and run counter to the stock’s gain; neither clearly explains the move.
- October 19 volume was 6,420 shares, below the cited 30-day average of 82,657; pre-market volume was unavailable.